Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medistim ASAFRA:MD1 +3.86%100 EV-to-EBIT is 23.09 as of Aug. 17, 2026, which is 7% below its 10-year median of 24.96. GuruFocus rates FRA:MD1 with a GF Score™ of 100/100 and a GF Value™ of €23.35 (Fairly Valued). The stock has 1 warning sign investors should review. Among 471 Medical Devices & Instruments companies, Medistim ASA ranks worse than 57.32% on this metric.
The historical rank and industry rank for Medistim ASA's EV-to-EBIT or its related term are showing as below:
FRA:MD1'
s EV-to-EBIT Range Over the Past 10 Years
Min: 15.82 Med: 24.96 Max: 65.11
Current: 21.94
During the past 13 years, the highest EV-to-EBIT of Medistim ASA was 65.11. The lowest was 15.82. And the median was 24.96.
FRA:MD1's EV-to-EBIT is ranked worse than 57.32% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 19.29
vs FRA:MD1: 21.94
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medistim ASA's Enterprise Value for the quarter that ended in Mar. 2026 was €321.63 Mil.
Medistim ASA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medistim ASA EV-to-EBIT Related Terms
Medistim ASA EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Medistim ASA's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medistim ASA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medistim ASA's EV-to-EBIT falls into.
Medistim ASA's current Enterprise Value is €382.41 Mil.
Medistim ASA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medistim ASA (FRA:MD1) has a EV-to-EBIT of 23.09 as of Aug. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medistim ASA and its competitors. This is near median its historical median of 24.96. Over the past decade, Medistim ASA's EV-to-EBIT has ranged from 15.82 to 65.11. According to the industry distribution chart, Medistim ASA ranks #270 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 57.3%.
Is Medistim ASA's EV-to-EBIT too high?
Medistim ASA's current EV-to-EBIT of 23.09 is near median its 10-year median of 24.96. Over the past 10 years, this metric has ranged from a low of 15.82 to a high of 65.11. The Medical Devices & Instruments industry median EV-to-EBIT is 19.29. Medistim ASA's value of 23.09 is 19.7% above this industry median. Based on the distribution chart, Medistim ASA ranks #270 out of 471 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medistim ASA has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #270 out of 471 companies for EV-to-EBIT. This places Medistim ASA in the lower half of its industry. The industry median EV-to-EBIT is 19.29. Medistim ASA's value of 23.09 is 19.7% above this benchmark. Historically, Medistim ASA's own EV-to-EBIT has ranged from 15.82 to 65.11 over the past decade. While the company's 10-year median is 24.96 vs. the industry median of 19.29, Medistim ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.29, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current EV-to-EBIT of 23.09 is 19.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medistim ASA and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current EV-to-EBIT is 23.09, which is near median its own 10-year median of 24.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (FRA:MD1) is currently considered Fairly Valued. The stock's GF Value™ is €23.35, compared to a current price of €21.50 — trading 7.9% below its estimated fair value. The current EV-to-EBIT is 23.09, which is near median its 10-year median of 24.96 and 19.7% above the Medical Devices & Instruments industry median of 19.29. Medistim ASA's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medistim ASA (FRA:MD1), the current EV-to-EBIT is 23.09 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (FRA:MD1) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of €21.50 is trading 7.9% below its estimated GF Value™ of €23.35.
GuruFocus considers Medistim ASA to be Fairly Valued.
Key valuation signals for FRA:MD1:
EV-to-EBIT: 23.09 (near median its 10-year median of 24.96)
GF Value™: €23.35 vs. price of €21.50 (7.9% below fair value)
Industry Position: 19.7% above the Medical Devices & Instruments median (#270 of 471)
No single metric tells the full story. See the FRA:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
100GF Score
Get the complete analysis for FRA:MD1
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MD1 has been successfully added to your 
